REGENXBIO released its Q3 2026 financial results and an operational update. The report comes alongside a Nov. 5 earnings call and ahead of anticipated Phase 3 s

REGENXBIO released its Q3 2026 financial results and an operational update. The report comes alongside a Nov. 5 earnings call and ahead of anticipated Phase 3 sura-vec program data, keeping investor focus on both cash position and clinical milestones.